文献速递泌尿生殖MRUS

基于风险的MRI导向诊断路径在疑似前列腺癌未活检男性中优于非风险导向路径:一项大型队列验证研究

Risk-based MRI-directed diagnostic pathway outperforms non-risk-based pathways in suspected prostate cancer biopsy-naïve men: a large cohort validation study.
PubMed 文献 · Eur Radiol · 2022-01-14

该单中心回顾性队列研究纳入499例有前列腺癌风险的未活检男性,比较五种诊断路径的活检避免率、临床显著前列腺癌检出率和临床不显著前列腺癌过度诊断。基于风险的MRI导向路径(低风险PI-RADS 1-3者不行活检)活检避免率最高(19.2%),临床显著前列腺癌检出率51.7%略低于参考路径52.9%但无显著差异,临床不显著前列腺癌检出率降至18.6%。决策曲线分析显示该路径在6.25%至65%阈值概率范围内净获益最大化。

要点

  • 基于风险的MRI导向路径在低风险PI-RADS 1-3男性中避免活检,活检避免率达19.2%。
  • 该路径临床显著前列腺癌检出率51.7%,与参考路径52.9%相比仅小幅降低。
  • 临床不显著前列腺癌检出率降至18.6%,较参考路径23.0%显著减少。

核心结论

  • 基于风险的MRI导向前列腺癌诊断路径在准确诊断、减少过度诊断和最大化避免活检之间达到最佳平衡。

研究设计与样本

  • 单中心回顾性队列研究,纳入499例有前列腺癌风险的未活检男性,均行PI-RADS合规前列腺MRI、经直肠超声融合引导靶向穿刺和系统穿刺,回顾性评估五种诊断路径。

关键影像表现/征象

  • 基于风险的路径在低风险PI-RADS 1-3男性中不行活检,活检避免率19.2%(96/499)。
  • MRI导向路径在PI-RADS 1-2男性中不行活检,活检避免率11.8%(59/499)。
  • 参考路径(以检出为重点)临床显著前列腺癌检出率52.9%(264/499),临床不显著前列腺癌检出率23.0%(115/499)。

诊断标准与关键数值

  • 临床显著前列腺癌定义为ISUP分级组≥2,临床不显著前列腺癌定义为ISUP分级=1。
  • MRI导向路径(PI-RADS 1-2不行活检)临床显著前列腺癌检出率52.1%(260/499),p=0.13;临床不显著前列腺癌检出率20.6%(103/499),p<0.01。
  • 基于风险的路径(低风险PI-RADS 1-3不行活检)临床显著前列腺癌检出率51.7%(258/499),p=0.04;与MRI导向路径相比p=0.625;临床不显著前列腺癌检出率18.6%(93/499),p<0.01。
  • 决策曲线分析显示基于风险的路径在阈值概率6.25%至65%范围内净获益最大化。

临床应用与阅片要点

  • 基于风险的MRI导向路径结合PSA密度、直肠指检和家族史等风险因素,进一步细化基于PI-RADS评分的初始分层。
  • 作者认为该证据应推动指南推荐在有显著前列腺癌风险的未活检男性中采用基于风险的MRI导向活检决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate and compare the performance of different proposed diagnostic pathways in a cohort of biopsy-naïve men at risk for prostate cancer (PCa), in terms of biopsy avoidance, accurate diagnosis of clinically significant prostate cancer (csPCa), and reduction in overdiagnosis of clinically insignificant cancer (cisPCa), with particular focus on a recently suggested "risk-based" MRI-directed diagnostic pathway.

METHODS: Single-center, retrospective cohort study, including 499 biopsy-naïve men at risk for PCa. All men underwent PI-RADS-compliant prostate MRI, transrectal ultrasound fusion-guided targeted (TBx), and systematic biopsy (SBx). Five diagnostic pathways were retrospectively evaluated and compared for. Outcome measures were biopsy avoidance, combined with missed csPCa and detected cisPCa. csPCa and cisPCa were defined as ISUP grade group ≥ 2 and grade = 1, respectively. Chi-square test was used for statistical analysis. Decision curve analyses were used to compare the benefits of the pathways across a range of biopsy thresholds.

RESULTS: The prevalence (detection-focused [reference] pathway) of csPCa and cisPCa was 52.9% (264/499) and 23.0% (115/499). MRI-focused pathway (no biopsy in PI-RADS 1-2 men) did not significantly reduce ISUP ≥ 2 cancer detection (52.1% (260/499); p = 0.13), but significantly reduced ISUP 1 cancers diagnosed (20.6% (103/499); p < 0.01), and biopsy avoidance was 11.8% (59/499). The risk-based MRI-directed pathway (no biopsy in low-risk PI-RADS 1-3 men) resulted in a small reduction of ISUP ≥ 2 diagnosed (51.7% (258/499); p = 0.04), however non-significant when compared to MRI-focused pathway (p = 0.625). Moreover, the risk-based pathway further reduced detection of ISUP 1 (18.6% (93/499); p < 0.01), and biopsy avoidance was 19.2% (96/499). Decision curve analysis showed maximized net benefit of the risk-based pathway, for the range of threshold probabilities between 6.25 and 65%.

CONCLUSION: The risk-based MRI-directed pathway for prostate cancer diagnosis was optimal in balancing accurate diagnosis, reducing overdiagnosis, and maximizing biopsy avoidance. This substantial evidence should inform guideline recommendations towards using "risk-based" MRI-directed biopsy decisions in biopsy-naïve men at risk of significant prostate cancer.

KEY POINTS: • Our study recognizes the added value of prostate MRI and MR-targeted biopsies in order to propose clinical diagnostic pathways for prostate cancer, towards maximizing the potential avoidance of unnecessary biopsies, while maintaining optimal detection rate of clinically significant prostate cancer. • The risk-based MRI-directed pathway incorporates risk factors such as PSA density, digital rectal examination, and family history to further refine the initial stratification of patients based on PI-RADS scores. • In this study, the risk-based pathway had the most optimal performance in terms of combination of outcomes, with the highest rate of biopsy avoidance (19.2%), while keeping a high detection rate of clinically significant prostate cancer (51.7%), when compared to the reference standard (52.9%).

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Bittencourt, Guricova, Zucker, et al. Risk-based MRI-directed diagnostic pathway outperforms non-risk-based pathways in suspected prostate cancer biopsy-naïve men: a large cohort validation study. Eur Radiol. 2022. PMID: 35028750. doi:10.1007/s00330-021-08407-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。